Live feed10:30:00·63dPRReleasevia QuantisnowCemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 TrialByQuantisnow·Wall Street's wire, on your screen.REGN· Regeneron Pharmaceuticals Inc.Health Care
